We previously showed that PD-L1 expression by qTP was significantly associated with categorical PD-L1 IHC expression [0, 1%–49%, ≥50% by 22C3 tumor proportion scoring (TPS)] in pathology reports accompanying NSCLC tumors with valid qTP data (20); however, IRS status and/or anti-PD-(L)1 therapy outcome were not available for the majority of that cohort. The gene discussed is IARS1; the disease is neoplasm.